Product Description
Mechanisms of Action: COMT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Parkinson's Disease
Phase 1: Parkinson's Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BIA-3202-202 | P2 |
Completed |
Parkinson's Disease |
2007-09-21 |
|
2006-001793-24 | P2 |
Completed |
Parkinson's Disease |
2007-05-31 |
|
BIA-3202-112 | P1 |
Completed |
Healthy Volunteers |
2006-12-01 |
|
BIA-6512-107 | P1 |
Completed |
Parkinson's Disease |
2006-10-20 |